The Relationship of Fas Promoter Polymorphisms and Breast Cancer Risk in North-West of Iran: A Haplotype and in Silico Analysis

It is better that the haplotypes and combined genotypes of fas molecular markers to be studied rather than each polymorphism, independently.
The present study aims at investigating whether the fas-1377G/A (rs2234767),-670A/G (rs1800682) polymorphisms as well as their combined genotypes and haplotypes affect the risk of developing breast tumors.
This study was conducted on 200 Iranian patients with breast cancer and 186 controls. The fas-1377G/A,-670A/G polymorphisms were determined, using tetra-ARMS-PCR and RFLP-PCR, respectively. The java stat online statistics package and SHEsis programs were used for data analysis. PNI modeler program was applied for in silico analysis.
The results of the present study did not show any significant differences in the genotype distribution of fas rs2234767, rs1800682 as well as their haplotypes and genotype combinations between cases and controls. Furthermore, in silico analysis indicated that fas-1377,-670 polymorphisms change the interaction of proteins with the promoter of fas.
The findings of this study proposed that the fas promoter variants did not have a major effect on the risk of breast cancer. Further studies are required to validate these conclusions across various populations. Based on in silico analysis, there was an altered binding pattern of proteins to the promoter of fas around the polymorphisms.